Blog
RSS FeedPosted by Michael Wonder on 20 May 2019
Europe responding to gene therapy challenge, but picture remains fragmented
20 May 2019 - Germany, Italy and England using outcomes-based deals. ...
Posted by Michael Wonder on 20 May 2019
ICER plans cloud-based tools to accelerate the use of value assessments in the US health care system
20 May 2019 - With a late 2019 launch target, ICER’s Evidence Compendium and Interactive Modeler will enable decision-makers within payers, ...
Posted by Michael Wonder on 20 May 2019
Health Technology Assessment Consumer Consultative Committee March 2019 meeting communiqué
20 May 2019 - A communiqué from the March 2019 meeting of the HTA Consumer Consultative Committee has been published. ...
Posted by Michael Wonder on 18 May 2019
NICE recommends Revlimid as multiple myeloma alternative
17 May 2019 - NICE has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight ...
Posted by Michael Wonder on 17 May 2019
Health technology assessment challenges in oncology: 20 years of Value in Health
16 May 2019 - Oncology treatments have changed from chemotherapies to targeted therapies and more recently immuno-oncology. ...
Posted by Michael Wonder on 15 May 2019
Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma
15 May 2019 - There are no serious disadvantages in terms of overall survival. ...
Posted by Michael Wonder on 15 May 2019
NICE recommends first ever treatment for children with rare muscle wasting condition
15 May 2019 - Children with the rare genetic disorder spinal muscular atrophy can now be treated with nusinersen after NICE ...
Posted by Michael Wonder on 14 May 2019
Analysis of sponsor hearings on PBAC decision making
14 May 2019 - Original research conducted by Melinda Flowers, Sean Lybrand and myself has been published on-line in the ...
Posted by Michael Wonder on 13 May 2019
Congress should revive the Office of Technology Assessment
13 May 2019 - In recent decades, the U.S. economy and society have been propelled forward by a boom in science ...
Posted by Michael Wonder on 13 May 2019
HTA frameworks for RA therapies need improvement, researchers say
13 May 2019 - Cost-effectiveness models for the treatment of rheumatoid arthritis first emerged in the early 2000s when highly effective ...
Posted by Michael Wonder on 13 May 2019
New cancer drugs approved for NHS use in Scotland
13 May 2019 - The Scottish Medicines Consortium accepted the use of new medicines to treat patients with breast and skin ...
Posted by Michael Wonder on 13 May 2019
SMC - May 2019 decisions
13 May 2019 - A medicine used to treat advanced breast cancer has today been accepted by the SMC for ...
Posted by Michael Wonder on 10 May 2019
What do transformational shifts mean in terms of ultimate outcomes and ‘value’ of medicines?
9 May 2019 - Emerging ‘one-time’ curative therapies create important new options for patients living with difficult and incurable health ...
Posted by Michael Wonder on 10 May 2019
Institute for Clinical and Economic Review's evidence report finds esketamine may benefit patients with treatment-resistant depression but exceeds cost-effectiveness thresholds
9 May 2019 - Midwest CEPAC to vote on overall value of esketamine during 23 May public meeting. ...
Posted by Michael Wonder on 09 May 2019
Lower price for MS drug paves the way for positive recommendation from NICE
9 May 2019 - A new, lower price for a drug to treat a rarer form of multiple sclerosis in adults ...